|
Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant Staphylococcus aureus confirmed nosocomial pneumonia in China |
Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, Chen CI, Hajek P, Patel DA, Gao X |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Tan SC, Wang X, Wu B, Kang H, Li Q, Chen Y, Chen CI, Hajek P, Patel DA, Gao X. Cost-effectiveness of linezolid versus vancomycin among patients with methicillin-resistant Staphylococcus aureus confirmed nosocomial pneumonia in China. Value in Health Regional Issues 2014; 3: 94-100 Indexing Status Subject indexing assigned by CRD MeSH Anti-Bacterial Agents; Anti-Infective Agents; Cost-Benefit Analysis; Humans; Oxazolidinones; Pneumonia; Staphylococcal Infections; Vancomycin AccessionNumber 22014023819 Date bibliographic record published 25/06/2014 |
|
|
|